Doxepin's effects on chronic pain and depression: A controlled study

Stuart R Hameroff, J. L. Weiss, J. C. Lerman

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Sixty patients with chronic pain in the low back or cervical spine concomitant with clinical depression were studied in a 6-week, randomized, double-blind comparison of doxepin and placebo. Significant improvements in the doxepin-treated group compared to placebo or to baseline values were seen on Hamilton depression scores. Global Assessment Scale scores, pain severity, percent of time pain felt, and effect of pain on activity, sleep, and muscle tension. Some improvements were observed after 1 week of treatment; the most improvement occurred at 6 weeks, when the mean doxepin dosage was approximately 200 mg/day and plasma doxepin and nordoxepin averaged 80 ng/ml. No significant harmful effects were observed. Neither plasma beta-endorphin nor enkephalin-like activity demonstrated significant differences from baseline. These data indicate that doxepin is a valuable treatment for patients with chronic pain and depression.

Original languageEnglish (US)
Pages (from-to)47-52
Number of pages6
JournalJournal of Clinical Psychiatry
Volume45
Issue number3 II
StatePublished - 1984

Fingerprint

Doxepin
Chronic Pain
Depression
Pain
Placebos
Muscle Tonus
beta-Endorphin
Enkephalins
Sleep
Spine
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Doxepin's effects on chronic pain and depression : A controlled study. / Hameroff, Stuart R; Weiss, J. L.; Lerman, J. C.

In: Journal of Clinical Psychiatry, Vol. 45, No. 3 II, 1984, p. 47-52.

Research output: Contribution to journalArticle

Hameroff, Stuart R ; Weiss, J. L. ; Lerman, J. C. / Doxepin's effects on chronic pain and depression : A controlled study. In: Journal of Clinical Psychiatry. 1984 ; Vol. 45, No. 3 II. pp. 47-52.
@article{34e7ca425a78453982a4c12d9296d489,
title = "Doxepin's effects on chronic pain and depression: A controlled study",
abstract = "Sixty patients with chronic pain in the low back or cervical spine concomitant with clinical depression were studied in a 6-week, randomized, double-blind comparison of doxepin and placebo. Significant improvements in the doxepin-treated group compared to placebo or to baseline values were seen on Hamilton depression scores. Global Assessment Scale scores, pain severity, percent of time pain felt, and effect of pain on activity, sleep, and muscle tension. Some improvements were observed after 1 week of treatment; the most improvement occurred at 6 weeks, when the mean doxepin dosage was approximately 200 mg/day and plasma doxepin and nordoxepin averaged 80 ng/ml. No significant harmful effects were observed. Neither plasma beta-endorphin nor enkephalin-like activity demonstrated significant differences from baseline. These data indicate that doxepin is a valuable treatment for patients with chronic pain and depression.",
author = "Hameroff, {Stuart R} and Weiss, {J. L.} and Lerman, {J. C.}",
year = "1984",
language = "English (US)",
volume = "45",
pages = "47--52",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "3 II",

}

TY - JOUR

T1 - Doxepin's effects on chronic pain and depression

T2 - A controlled study

AU - Hameroff, Stuart R

AU - Weiss, J. L.

AU - Lerman, J. C.

PY - 1984

Y1 - 1984

N2 - Sixty patients with chronic pain in the low back or cervical spine concomitant with clinical depression were studied in a 6-week, randomized, double-blind comparison of doxepin and placebo. Significant improvements in the doxepin-treated group compared to placebo or to baseline values were seen on Hamilton depression scores. Global Assessment Scale scores, pain severity, percent of time pain felt, and effect of pain on activity, sleep, and muscle tension. Some improvements were observed after 1 week of treatment; the most improvement occurred at 6 weeks, when the mean doxepin dosage was approximately 200 mg/day and plasma doxepin and nordoxepin averaged 80 ng/ml. No significant harmful effects were observed. Neither plasma beta-endorphin nor enkephalin-like activity demonstrated significant differences from baseline. These data indicate that doxepin is a valuable treatment for patients with chronic pain and depression.

AB - Sixty patients with chronic pain in the low back or cervical spine concomitant with clinical depression were studied in a 6-week, randomized, double-blind comparison of doxepin and placebo. Significant improvements in the doxepin-treated group compared to placebo or to baseline values were seen on Hamilton depression scores. Global Assessment Scale scores, pain severity, percent of time pain felt, and effect of pain on activity, sleep, and muscle tension. Some improvements were observed after 1 week of treatment; the most improvement occurred at 6 weeks, when the mean doxepin dosage was approximately 200 mg/day and plasma doxepin and nordoxepin averaged 80 ng/ml. No significant harmful effects were observed. Neither plasma beta-endorphin nor enkephalin-like activity demonstrated significant differences from baseline. These data indicate that doxepin is a valuable treatment for patients with chronic pain and depression.

UR - http://www.scopus.com/inward/record.url?scp=0021280966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021280966&partnerID=8YFLogxK

M3 - Article

C2 - 6321454

AN - SCOPUS:0021280966

VL - 45

SP - 47

EP - 52

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 3 II

ER -